Answers are grounded in this paper and cite their sources.
OBJECTIVE: Black patients with systemic sclerosis (scleroderma) have more severe disease than White patients. We investigated whether racial differences in therapeutic responses to mycophenolate mofetil (MMF) could explain this differential disease severity. METHODS: Self-identified Black and White patients with scleroderma who had MMF exposure were selected from the Johns Hopkins Scleroderma Center Research Registry. We used linear mixed effects models to study the trajectory of forced vital capacity % predicted (pFVC) and modified Rodnan skin scores (mRSS) during follow-up. RESULTS: Among 662 patients with measured baseline pFVC, the average (SD) baseline pFVC was 64.3 (15.6) for Black patients and 86.9 (18.6) for White patients (p<0.001). During follow-up, the estimated annual change ±SE in pFVC among Black patients was -0.53±0.46 pre-MMF and -0.58±0.27 post-treatment (pre-post difference of -0.04±0.54 (p=0.939)). Among White patients, estimated annual changes in pFVC pre- and post-MMF were -1.20± 0.23 and -0.56±0.13, with a pre-post difference of +0.64±0.27 (p=0.019). Among 452 patients with diffuse scleroderma, the baseline mRSS was 17.2 (SD 10.1) for Black patients and 21.4 (SD 11.1) for White patients (p<0.001). The estimated difference in annual change in mRSS post-MMF treatment compared to pre-treatment was -0.87±0.32 for Black patients, compared to -0.68±0.16 among White patients (p=0.598). CONCLUSION: Black patients have more severe pulmonary disease at presentation. While Black and White patients have similar rates of change in pFVC and mRSS after MMF exposure, Black patients did not have a meaningful difference in pFVC change post-MMF compared to pre-MMF, suggesting further study is needed in this population.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: